Sodium- and chloride-dependent creatine transporter 1 (SLC6A8) (SLC6A8)

Sodium- and chloride-dependent creatine transporter 1 (SLC6A8) is a specialized transmembrane protein that facilitates the uptake of creatine into tissues with high and fluctuating energy demands, such as the brain, skeletal muscle, and heart [15][19]. As a member of the solute carrier family 6, it utilizes sodium and chloride electrochemical gradients to maintain cellular creatine pools, which are essential for the creatine-phosphocreatine shuttle that buffers ATP levels during metabolic stress [18][21]. Genetic mutations in the SLC6A8 gene lead to X-linked Creatine Transporter Deficiency (CTD), a syndrome characterized by severe neurological symptoms including intellectual disability, seizures, and speech delay [3][19]. In oncology, SLC6A8 is frequently upregulated in metabolically active and hypoxic tumors, such as colorectal cancer and glioblastoma, to sustain bioenergetic homeostasis and promote survival [2][19]. This has led to the development of therapeutic inhibitors like Ompenaclid (RGX-202), which are currently being evaluated in clinical trials for their ability to starve cancer cells of energy and induce apoptosis [4][7]. Additionally, recent research has highlighted the transporter's role in the central nervous system, where creatine may function as a neurotransmitter or neuromodulator [19].

Other names

Creatine transporterCRTSLC6A8CT1CRTRSodium-dependent creatine transporterCreatine

Drugs targeting this transporter primarily act through competitive inhibition to block cellular creatine uptake, which disrupts the creatine-phosphocreatine shuttle and depletes intracellular energy reserves in cancer cells [2][18]. In the context of genetic deficiency, emerging therapeutic strategies involve pharmacological chaperones or 'correctors' designed to stabilize mutant transporter proteins and facilitate their proper trafficking to the plasma membrane [3].